10.05.10
Results of a randomized study conducted to evaluate the effects of a synbiotic preparation (ProbioKid from Institut Rosell-Lallemand) on the incidence of infectious episodes in children during the winter period indicated a reduction in the relative risks of any infectious event by 25% compared to placebo.
ProbioKid (distributed in France by Laboratoires Urgo under brand name Immunostim) is the association of three well-characterized probiotic strains from the Institut Rosell collection and a prebiotic.
The randomized, double-blind, placebo-controlled pilot study, conducted in partnership with Laboratoires Urgo (France), showed that ProbioKid was able to reduce the relative risks of any infectious event by 25% in children during the winter period, as compared to placebo. This result is backed by mechanistic and pre-clinical studies that showed the ability of this particular probiotic preparation to modulate the different types of immune response (Th1 and Th2), with potential implications in the management and prevention of allergic diseases such as asthma.
The trial suggests a clinically relevant beneficial effect of a 3-month, daily synbiotic regimen for a school age population of 3-7 year-olds. For further information: www.institut-rosell-lallemand.com
ProbioKid (distributed in France by Laboratoires Urgo under brand name Immunostim) is the association of three well-characterized probiotic strains from the Institut Rosell collection and a prebiotic.
The randomized, double-blind, placebo-controlled pilot study, conducted in partnership with Laboratoires Urgo (France), showed that ProbioKid was able to reduce the relative risks of any infectious event by 25% in children during the winter period, as compared to placebo. This result is backed by mechanistic and pre-clinical studies that showed the ability of this particular probiotic preparation to modulate the different types of immune response (Th1 and Th2), with potential implications in the management and prevention of allergic diseases such as asthma.
The trial suggests a clinically relevant beneficial effect of a 3-month, daily synbiotic regimen for a school age population of 3-7 year-olds. For further information: www.institut-rosell-lallemand.com